A phase II trial of trastuzumab, Neupogen [filgrastim], and vinorelbine investigating the effects on immune function and clinical outcomes in patients with metastatic breast cancer overexpressing HER-2/neu.

Trial Profile

A phase II trial of trastuzumab, Neupogen [filgrastim], and vinorelbine investigating the effects on immune function and clinical outcomes in patients with metastatic breast cancer overexpressing HER-2/neu.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 20 Oct 2011

At a glance

  • Drugs Filgrastim; Granulocyte colony-stimulating factors; Trastuzumab; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Oct 2011 Trial phase changed from II to II/III as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Actual number of patients (23) added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top